AHS 2022 | The endocannabinoid system and migraine pain

Clinical endocannabinoid deficiency in migraine has been addressed since the mid-2000s, yet limited work has been conducted on how this contributes to the disease status. Tally Largent-Milnes, PhD, University of Arizona, College of Medicine, Tucson, AZ, discusses the significance of the endocannabinoid system in headache disorders. Current observations on individuals with chronic migraine demonstrate lower levels of circulating endocannabinoid lipids in the blood and cerebrospinal fluid. To understand the role of the endocannabinoid system in migraine, studies have looked at the lipid mediators anandamide (AEA) and 2-arachidonoylglycerol (2-AG) as well as the enzymes responsible for their synthesis and degradation. This interview took place at the 2022 American Headache Society (AHS) meeting in Denver, CO.